Innova Captab Limited reported healthy results for Q4 FY26

Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its audited financial results for the quarter and year ended March 31st, 2026.

Q4FY26 vs. Q4 FY25 Performance:

- Revenue from Operations registered strong growth of 42.3% to ₹ 447.8 crores vs. ₹ 314.7 crores

- Recorded EBITDA growth of 30.5% to ₹ 66.7 crores vs. ₹ 51.1 crores. EBITDA margin for the quarter was 14.9%

- PAT for the quarter was ₹ 38.1 crores, registering growth of 28.8%. PAT margin was 8.5%

FY26 vs. FY25 Performance:

- Revenue from Operations for FY26 cumulated to ₹ 1,630.0 crores vs. ₹ 1,243.7 crores in FY25 clocking growth of 31.1%

- EBITDA for FY26 stood at ₹ 250.3 crores vs. ₹ 198.2 crores in FY25, growing at 26.3%. EBITDA margin was 15.4%

- Profit after Tax was ₹ 140.9 crores. PAT margin came in at 8.6%

Commenting on the company's performance, Mr. Vinay Lohariwala, Managing Director, Innova Captab Limited, said "Innova Captab Ltd has a strong performance with YoY revenue growth of 42% in Q4 FY26 and has delivered its highest-ever annual revenue with a growth of 31% in FY26. This strong performance underscores disciplined execution across our operations.

This milestone performance was driven by sustained momentum across our CDMO and branded generics businesses, supported by an expanding product portfolio and increasing customer engagement.

Operational excellence remains central, backed by state-of-the-art manufacturing infrastructure and stringent quality processes. During the year, we received key certifications including UK-MHRA for our Baddi facility and PIC/S for our Jammu blocks, enhancing our presence in regulated markets.

The Jammu facility has completed its first full year of operations and is ramping up well, with multiple marquee clients successfully completing regulatory and customer audits.

With multiple growth levers in place, we remain confident in sustaining momentum and delivering long-term value to our stakeholders."

Shares of Innova Captab Limited was last trading in BSE at Rs. 875.45 as compared to the previous close of Rs. 863.05. The total number of shares traded during the day was 8899 in over 601 trades.

The stock hit an intraday high of Rs. 899.90 and intraday low of 828.85. The net turnover during the day was Rs. 7727688.00.

Source : Equity Bulls

Keywords

InnovaCaptab Pharmaceuticals INE0DUT01020 Q4FY26 Q4FY2026 FY26 FY2026 ResultUpdate